Unknown

Dataset Information

0

Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors.


ABSTRACT: Binding of ?5?1 and ?v?3/?5 integrin receptors on the endothelium to their fibronectin substrate in the extracellular matrix has been targeted as a possible means of blocking tumor angiogenesis and tumor growth. However, clinical trials of blocking antibodies and peptides have been disappointing despite promising preclinical results, leading to questions about the mechanism of the inhibitors and the reasons for their failure. Here, using tissue-specific and inducible genetics to delete the ?5 and ?v receptors in the endothelium or their fibronectin substrate, either in the endothelium or globally, we show that both are dispensable for tumor growth, in transplanted tumors as well as spontaneous and angiogenesis-dependent RIP-Tag-driven pancreatic adenocarcinomas. In the nearly complete absence of fibronectin, no differences in vascular density or the deposition of basement membrane laminins, ColIV, Nid1, Nid2, or the TGF? binding matrix proteins, fibrillin-1 and -2, could be observed. Our results reveal that fibronectin and the endothelial fibronectin receptor subunits, ?5 and ?v, are dispensable for tumor angiogenesis, suggesting that the inhibition of angiogenesis induced by antibodies or small molecules may occur through a dominant negative effect, rather than a simple functional block.

SUBMITTER: Murphy PA 

PROVIDER: S-EPMC4373772 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors.

Murphy Patrick A PA   Begum Shahinoor S   Hynes Richard O RO  

PloS one 20150325 3


Binding of α5β1 and αvβ3/β5 integrin receptors on the endothelium to their fibronectin substrate in the extracellular matrix has been targeted as a possible means of blocking tumor angiogenesis and tumor growth. However, clinical trials of blocking antibodies and peptides have been disappointing despite promising preclinical results, leading to questions about the mechanism of the inhibitors and the reasons for their failure. Here, using tissue-specific and inducible genetics to delete the α5 an  ...[more]

Similar Datasets

| S-EPMC6063507 | biostudies-literature
| S-EPMC3177315 | biostudies-literature
| S-EPMC7408126 | biostudies-literature
| S-EPMC5674886 | biostudies-literature
| S-EPMC2234046 | biostudies-literature
| S-EPMC3193578 | biostudies-literature
| S-EPMC8916723 | biostudies-literature
| S-EPMC6521375 | biostudies-literature
| S-EPMC5528558 | biostudies-literature
| S-EPMC1894776 | biostudies-literature